source
- Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholismAltimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a wee…
- Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pillPlus news about Outlook Therapeutics, Gossamer Bio, Apnimed and Entera Bio. 📈 Yarrow closes merger to go public: Yarrow Bioscience is developing an anti-TSHR antibody for Graves’ disease and thyro…